{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:39:14Z","timestamp":1790087954016,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Benralizumab, a monoclonal antibody targeting IL-5 receptors, reduces exacerbations and oral corticosteroid requirements for severe, uncontrolled eosinophilic asthma. In Japan, geographic disparities in asthma outcomes suggest differential prescribing and access. This study aimed to quantify regional prescribing variations for benralizumab nationwide. Using Japan\u2019s National Database (NDB) of insurance claims (2009\u20132019), benralizumab standardized claim ratios (SCRs) were calculated for 47 prefectures. Correlations between SCRs and other biologics\u2019 SCRs, economic variables like average income, and physician densities were evaluated through univariate analysis and multivariate regressions. Income-related barriers to optimal prescribing were examined. Wide variation emerged in benralizumab SCRs, from 40.1 to 184.2 across prefectures. SCRs strongly correlated with omalizumab (r\u2009=\u20090.61, p\u2009&lt;\u20090.00001) and mepolizumab (r\u2009=\u20090.43, p\u2009=\u20090.0024). Average monthly income also positively correlated with benralizumab SCRs (r\u2009=\u20090.45, p\u2009=\u20090.0016), whereas lifestyle factors were insignificant. Respiratory specialist density modestly correlated with SCRs (r\u2009=\u20090.29, p\u2009=\u20090.047). In multivariate regressions, average income remained the most robust predictor (B\u2009=\u20090.74, p\u2009=\u20090.022). Benralizumab SCRs strongly associate with income metrics more than healthcare infrastructure\/population factors. Many regions show low SCRs, constituting apparent prescribing gaps. Access barriers for advanced asthma therapies remain inequitable among Japan\u2019s income strata. Addressing affordability alongside specialist allocation can achieve better prescribing quality and asthma outcomes.<\/jats:p>","DOI":"10.1038\/s41598-024-65407-4","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T14:02:46Z","timestamp":1719928966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Geographic and economic influences on benralizumab prescribing for severe asthma in Japan"],"prefix":"10.1038","volume":"14","author":[{"given":"Nobuaki","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Somekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayami","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momo","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sousuke","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Murohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Horita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"1","key":"65407_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13223-022-00676-0","volume":"18","author":"WJ Calhoun","year":"2022","unstructured":"Calhoun, W. J. & Chupp, G. L. The new era of add-on asthma treatments: Where do we stand? Allergy Asthma Clin. Immunol. 18(1), 42. https:\/\/doi.org\/10.1186\/s13223-022-00676-0 (2022).","journal-title":"Allergy Asthma Clin. Immunol."},{"issue":"4","key":"65407_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","volume":"157","author":"E Wang","year":"2020","unstructured":"Wang, E. et al. Characterization of severe asthma worldwide. Chest 157(4), 790\u2013804. https:\/\/doi.org\/10.1016\/j.chest.2019.10.053 (2020).","journal-title":"Chest"},{"issue":"10056","key":"65407_CR3","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald, J. M. et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388(10056), 2128\u20132141. https:\/\/doi.org\/10.1016\/S0140-6736(16)31322-8 (2016).","journal-title":"Lancet"},{"issue":"10056","key":"65407_CR4","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker, E. R. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388(10056), 2115\u20132127. https:\/\/doi.org\/10.1016\/S0140-6736(16)31324-1 (2016).","journal-title":"Lancet"},{"issue":"4","key":"65407_CR5","doi-asserted-by":"publisher","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","volume":"52","author":"ER Bleecker","year":"2018","unstructured":"Bleecker, E. R. et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur. Respir. J. 52(4), 1800936. https:\/\/doi.org\/10.1183\/13993003.00936-2018 (2018).","journal-title":"Eur. Respir. J."},{"issue":"7","key":"65407_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.21037\/atm.2020.04.01","volume":"8","author":"T Izumo","year":"2020","unstructured":"Izumo, T. et al. Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): A prospective study. Ann. Transl. Med. 8(7), 438\u2013438. https:\/\/doi.org\/10.21037\/atm.2020.04.01 (2020).","journal-title":"Ann. Transl. Med."},{"issue":"5","key":"65407_CR7","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jaip.2019.03.008","volume":"7","author":"JG Krings","year":"2019","unstructured":"Krings, J. G., McGregor, M. C., Bacharier, L. B. & Castro, M. Biologics for severe asthma: Treatment-specific effects are important in choosing a specific agent. J. Allergy Clin. Immunol. Pract. 7(5), 1379\u20131392. https:\/\/doi.org\/10.1016\/j.jaip.2019.03.008 (2019).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"65407_CR8","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2147\/PPA.S198953","volume":"13","author":"HL Gelhorn","year":"2019","unstructured":"Gelhorn, H. L., Balantac, Z., Ambrose, C. S., Chung, Y. N. & Stone, B. Patient and physician preferences for attributes of biologic medications for severe asthma. Patient Prefer Adher. 13, 1253\u20131268. https:\/\/doi.org\/10.2147\/PPA.S198953 (2019).","journal-title":"Patient Prefer Adher."},{"key":"65407_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/JAA.S354062","volume":"15","author":"F Hardtstock","year":"2022","unstructured":"Hardtstock, F. et al. Use of biologic therapies in the treatment of asthma\u2014A comparative real world data analysis on healthcare resource utilization and costs before and after therapy initiation. J. Asthma Allergy 15, 407\u2013418. https:\/\/doi.org\/10.2147\/JAA.S354062 (2022).","journal-title":"J. Asthma Allergy"},{"issue":"2","key":"65407_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jaip.2019.08.024","volume":"8","author":"JW Inselman","year":"2020","unstructured":"Inselman, J. W., Jeffery, M. M., Maddux, J. T., Shah, N. D. & Rank, M. A. Trends and disparities in asthma biologic use in the United States. J. Allergy Clin. Immunol. Pract. 8(2), 549\u2013554. https:\/\/doi.org\/10.1016\/j.jaip.2019.08.024 (2020).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"11","key":"65407_CR11","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1016\/j.jaip.2021.01.039","volume":"9","author":"AT Akenroye","year":"2021","unstructured":"Akenroye, A. T., Heyward, J., Keet, C. & Alexander, G. C. Lower use of biologics for the treatment of asthma in publicly insured individuals. J. Allergy Clin. Immunol. Pract. 9(11), 3969\u20133976. https:\/\/doi.org\/10.1016\/j.jaip.2021.01.039 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"65407_CR12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jaci.2017.04.036","volume":"141","author":"JC Cardet","year":"2018","unstructured":"Cardet, J. C. et al. Income is an independent risk factor for worse asthma outcomes. J. Allergy Clin. Immunol. 141(2), 754\u2013760. https:\/\/doi.org\/10.1016\/j.jaci.2017.04.036 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"65407_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/19420862.2017.1392425","volume":"10","author":"M Godar","year":"2018","unstructured":"Godar, M., Blanchetot, C., de Haard, H., Lambrecht, B. N. & Brusselle, G. Personalized medicine with biologics for severe type 2 asthma: Current status and future prospects. MAbs 10(1), 34\u201345. https:\/\/doi.org\/10.1080\/19420862.2017.1392425 (2018).","journal-title":"MAbs"},{"issue":"4","key":"65407_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/thoraxjnl-2013-204114","volume":"70","author":"S O\u2019Neill","year":"2015","unstructured":"O\u2019Neill, S. et al. The cost of treating severe refractory asthma in the UK: An economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 70(4), 376\u2013378. https:\/\/doi.org\/10.1136\/thoraxjnl-2013-204114 (2015).","journal-title":"Thorax"},{"issue":"3","key":"65407_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.anai.2021.03.015","volume":"127","author":"J Reibman","year":"2021","unstructured":"Reibman, J. et al. Clinical and economic burden of severe asthma among US patients treated with biologic therapies. Ann. Allergy Asthma Immunol. 127(3), 318\u2013325. https:\/\/doi.org\/10.1016\/j.anai.2021.03.015 (2021).","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"6","key":"65407_CR16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","volume":"76","author":"JL Nam","year":"2017","unstructured":"Nam, J. L. et al. Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 76(6), 1113\u20131136. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210713 (2017).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"65407_CR17","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s13063-022-06543-y","volume":"23","author":"S Lei","year":"2022","unstructured":"Lei, S., Li, Z., Zhang, X. & Zhou, S. Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: A study protocol for a non-inferiority randomized, controlled, single-blind trial. Trials 23(1), 600. https:\/\/doi.org\/10.1186\/s13063-022-06543-y (2022).","journal-title":"Trials"},{"issue":"1","key":"65407_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.iac.2004.09.005","volume":"25","author":"BG Bender","year":"2005","unstructured":"Bender, B. G. & Bender, S. E. Patient-identified barriers to asthma treatment adherence: Responses to interviews, focus groups, and questionnaires. Immunol. Allergy Clin. N. Am. 25(1), 107\u2013130. https:\/\/doi.org\/10.1016\/j.iac.2004.09.005 (2005).","journal-title":"Immunol. Allergy Clin. N. Am."},{"issue":"6","key":"65407_CR19","doi-asserted-by":"publisher","first-page":"1701782","DOI":"10.1183\/13993003.01782-2017","volume":"50","author":"J Bousquet","year":"2017","unstructured":"Bousquet, J. et al. Care pathways for the selection of a biologic in severe asthma. Eur. Respir. J. 50(6), 1701782. https:\/\/doi.org\/10.1183\/13993003.01782-2017 (2017).","journal-title":"Eur. Respir. J."},{"issue":"3","key":"65407_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1046\/j.1369-6513.2002.00181.x","volume":"5","author":"A Caress","year":"2002","unstructured":"Caress, A., Luker, K., Woodcock, A. & Beaver, K. A qualitative exploration of treatment decision-making role preference in adult asthma patients. Health Expect. 5(3), 223\u2013235. https:\/\/doi.org\/10.1046\/j.1369-6513.2002.00181.x (2002).","journal-title":"Health Expect."},{"issue":"1","key":"65407_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.acap.2015.06.010","volume":"16","author":"SJ Mitchell","year":"2016","unstructured":"Mitchell, S. J., Bilderback, A. L. & Okelo, S. O. Racial disparities in asthma morbidity among pediatric patients seeking asthma specialist care. Acad. Pediatr. 16(1), 64\u201367. https:\/\/doi.org\/10.1016\/j.acap.2015.06.010 (2016).","journal-title":"Acad. Pediatr."},{"issue":"12","key":"65407_CR22","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1164\/rccm.200808-1233OC","volume":"178","author":"K Wells","year":"2008","unstructured":"Wells, K. et al. Race-ethnic differences in factors associated with inhaled steroid adherence among adults with asthma. Am. J. Respir. Crit. Care Med. 178(12), 1194\u20131201. https:\/\/doi.org\/10.1164\/rccm.200808-1233OC (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9796","key":"65407_CR23","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S0140-6736(11)60828-3","volume":"378","author":"N Ikegami","year":"2011","unstructured":"Ikegami, N. et al. Japanese universal health coverage: Evolution, achievements, and challenges. Lancet 378(9796), 1106\u20131115. https:\/\/doi.org\/10.1016\/S0140-6736(11)60828-3 (2011).","journal-title":"Lancet"},{"issue":"1","key":"65407_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31662\/jmaj.2018-0016","volume":"2","author":"S Matsuda","year":"2019","unstructured":"Matsuda, S. Health policy in Japan\u2014Current situation and future challenges. JMA J. 2(1), 1\u201310. https:\/\/doi.org\/10.31662\/jmaj.2018-0016 (2019).","journal-title":"JMA J."},{"issue":"1","key":"65407_CR25","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1038\/s41598-023-31856-6","volume":"13","author":"H Matsumoto","year":"2023","unstructured":"Matsumoto, H. et al. Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan. Sci. Rep. 13(1), 5208. https:\/\/doi.org\/10.1038\/s41598-023-31856-6 (2023).","journal-title":"Sci. Rep."},{"key":"65407_CR26","unstructured":"Japan Cabinet Office. Regional Differences in Healthcare Delivery Status. https:\/\/www.cao.go.jp\/keizai-shimon\/kaigi\/special\/reform\/mieruka\/tiikisa.html."},{"key":"65407_CR27","unstructured":"Ministry of Health. The Basic Survey on Wage Structure."},{"key":"65407_CR28","unstructured":"Ministry of Health. 7th NDB Open Data. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000177221_00011.html."},{"key":"65407_CR29","unstructured":"Central Secretariat Service & Ministry of Education. The Basic School Survey. https:\/\/www.e-stat.go.jp\/stat-search\/files?page=1&toukei=00400001&tstat=000001011528."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65407-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65407-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65407-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T14:10:00Z","timestamp":1719929400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-65407-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["65407"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-65407-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15190"}}